Kanser di próstata ta e di dos kanser mas komun serka hende hòmber mundialmente, ku un kantidat di 1.276 mion kaso nobo den 2018, ku ta representá 7.1% di tur kaso di kanser serka hende hòmber.
E tasa di mortalidat pa kanser di próstata tambe ta haltu, ku un kantidat di 37.005 morto na mundu den 2018.
Sinembargo, e tasa di mortalidad ta varia hopi segun region, cu West Africa tin e di cinco riesgo mas halto pa mortalidad di cancer di prostata na mundo, y Nigeria tin e poblacion y economia mas grandi den e region aki.
Na Nigeria, kanser di próstata ta e kanser mas komun i mas mortal pa hende hòmber, ku un kantidat di 32.8 kaso i 16.3 morto pa kada 100,000 hende hòmber.
Esaki ta mas ku dòbel di e kantidat di morto na Nort Amérika.
Detekshon lat di e malesa, rekursonan limitá pa screening i detekshon, i ménos dokumentashon i reportahe di kasonan ta kontribuí na e tasa haltu di mortalidat na Nigeria.
Na Estádos Unídos kanser di próstata ta e di dos kousa mas komun di morto pa kanser serka hende hòmber, ku aproksimadamente 40.000 hende hòmber ta muri di e malesa tur aña.
E tasa di mortalidat di kanser di próstata a baha poko poko for di komienso di añanan 90, pero e ta keda un preokupashon di salú importante.
En general, kanser di próstata ta un malesa mortal, spesialmente den regionnan ku tin akseso limitá na kuido médiko i rekursonan pa hasi screening.
Sinembargo, detekshon i tratamentu trempan por mehorá e resultado i redusí e kantidat di morto.
Nakata S, Takahashi H, Ohtake N, Takei T, Yamanaka H: Trends and characteristics in prostate cancer mortality in Japan. Int J Urol. 2000, 7 (7): 254-7.
Pishgar F, Ebrahimi H, Saeedi Moghaddam S, Fitzmaurice C, Amini E: Global, Regional and National Burden of Prostate Cancer, 1990 to 2015: Results from the Global Burden of Disease Study 2015. J Urol. 2018, 199 (5): 1224-1232.
Cai Q, Chen Y, Zhang D, Pan J, Xie Z, Xu C, Li S, Zhang X, Gao Y, Hou J, Guo X, Zhou X, Zhang B, Ma F, Zhang W, Lin G, Xin Z, Niu Y, Wang Y: Estimates of over-time trends in incidence and mortality of prostate cancer from 1990 to 2030. Transl Androl Urol. 2020, 9 (2): 196-209.
Feletto E, Bang A, Cole-Clark D, Chalasani V, Rasiah K, Smith DP: An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high? World J Urol. 2015, 33 (11): 1677-87.
Taksler GB, Keating NL, Cutler DM: Explaining racial differences in prostate cancer mortality. Cancer. 2012, 118 (17): 4280-9.
['Disclaimer: médiko']
['E website aki ta pa informashon i edukashon so i no ta pa duna konseho médiko òf servisio profeshonal.']
['E informashon ku ta ser duná no mester ser usá pa diagnostiká òf trata un problema di salú òf malesa, i esnan ku ta buska konseho médiko personal mester konsultá ku un dòkter ku tin un pèrmit di traha.']
['Por fabor nota e reda neuronal ku ta generá kontesta na e preguntanan, ta spesialmente inakusá ora ta trata di kontenido numériko. Por ehèmpel, e kantidat di hende diagnostiká ku un malesa spesífiko.']
['Semper busca conseho di bo dokter of otro profesional di salud cualifica tocante un condicion medico. Nunca ignora conseho medico profesional of tarda pa busca esaki pa motibo di algo cu bo a lesa riba e website aki. Si bo ta kere cu bo por tin un emergencia medico, yama 911 of bay na e sala di emergencia mas cerca di bo mesora.']
['Copyright: Copyright']
['E Digital Millennium Copyright Act di 1998, 17 U.S.C. § 512 (e DMCA) ta duna derechi di rekurso pa doñonan di derechi di outor ku ta kere ku material ku ta aparesé riba internet ta violá nan derechi bou di lei di derechi di outor di Merka. ']
['Si bo ta kere di buena fe ku kualke kontenido òf material ku ta disponibel riba nos website òf servisio ta violá bo derechi di outor, abo (òf bo representante) por manda nos un notifikashon pa pidi pa kita e kontenido òf material òf pa blokia akseso na dje.']
["Mester manda e anunsio por eskrito via e-mail (wak e sekshon 'Kontacto' pa e-mail adrès)."]
['E DMCA ta eksigí ku bo notifikashon di violashon di derechi di outor ta inkluí e siguiente informashon: (1) deskripshon di e obra ku ta suheto di violashon; (2) deskripshon di e kontenido ku ta viola i informashon sufisiente pa nos por lokalisá e kontenido; (3) informashon di kontakto, inkluyendo bo adrès, number di telefòn i email; (4) un deklarashon di bo ku bo ta kere ku e kontenido no ta outorisá pa e doño di derechi di outor, su agente òf lei.']
['(5) un deklarashon di bo, firma bou di pena di huramentu falsu, ku e informashon den e notifikashon ta korekto i ku bo tin outoridat pa hasi uso di e derechonan di outor ku ta ser akusá di a wòrdu infringi;']
['i (6) un firma físiko òf elektróniko di e doño di derechi di outor òf un persona outorisá pa aktua na nòmber di e doño di derechi di outor.']
['Si bo no duna tur informashon ariba menshoná, e tratamentu di bo keho por tarda.']
['Kontakto']
['Por fabor manda nos un email ku kualke pregunta/sugerencia.']
How deadly is prostate cancer?
Prostate cancer is the second most common cancer in men worldwide, with an estimated 1.276 million new cases reported in 2018, representing 7.1% of all cancer cases in men.
The mortality rate for prostate cancer is also high, with an estimated 37,005 deaths worldwide in 2018.
However, the mortality rate varies greatly by region, with Western Africa having the fifth-highest risk for prostate cancer mortality in the world, and Nigeria having the largest population and economy in this region.
In Nigeria, prostate cancer is both the most common and most deadly cancer for men, with an estimated 32.8 cases and 16.3 deaths per 100,000 men.
This is more than double the death rate in North America.
Late detection of the disease, limited resources for screening and detection, and decreased documentation and reporting of cases contribute to the high mortality rate in Nigeria.
In the United States, prostate cancer is the second most common cause of cancer death in men, with approximately 40,0000 men dying from the disease each year.
The prostate cancer death rate has been slowly decreasing since the early 1990s, but it remains a significant health concern.
Overall, prostate cancer is a deadly disease, particularly in regions with limited access to medical care and screening resources.
However, early detection and treatment can significantly improve outcomes and reduce mortality rates.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['Tokante']
['BioMedLib ta usa kòmpiuter outomátiko (algoritmo di siñamentu di mashin) pa generá par di pregunta i kontesta.']
['Nos ta kuminsá ku 35 mion publikashon biomédico di PubMed/Medline. Tambe página di RefinedWeb.']
